Low Grade Glioma

Categories: Cancer diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Low Grade Glioma

MalaCards integrated aliases for Low Grade Glioma:

Name: Low Grade Glioma 11 14
Benign Glioma 11


External Ids:

Disease Ontology 11 DOID:0080829
NCIt 49 C132067

Summaries for Low Grade Glioma

Disease Ontology: 11 A cell type benign neoplasm that has material basis in glial cells (astrocytes, oligodendrocytes or ependymocytes).

MalaCards based summary: Low Grade Glioma, also known as benign glioma, is related to glioma susceptibility 1 and oligoastrocytoma. An important gene associated with Low Grade Glioma is KAZALD1 (Kazal Type Serine Peptidase Inhibitor Domain 1), and among its related pathways/superpathways are Disease and Pre-NOTCH Expression and Processing. The drugs Lomustine and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and cortex, and related phenotypes are neoplasm and cellular

Related Diseases for Low Grade Glioma

Diseases related to Low Grade Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 587)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 32.8 TP53 MIR21 IDH2 IDH1 H3-3A
2 oligoastrocytoma 32.8 MGMT IDH2
3 glioma 32.7 TP53 NF1 MIR21 MGMT IDH2 IDH1
4 pilocytic astrocytoma 32.5 TP53 SERPINA3 NF1 MGMT KIAA1549 IDH2
5 pleomorphic xanthoastrocytoma 32.3 TP53 SERPINA3 NF1 MGMT KIAA1549 IDH2
6 diffuse astrocytoma 32.2 TP53 SERPINA3 NF1 MGMT KIAA1549 KDM4C
7 oligodendroglioma 31.9 TP53 NF1 MGMT IDH2 IDH1 EGFR
8 neurofibromatosis 31.9 TSC2 TP53 NF1 EGFR
9 neurofibromatosis, type i 31.8 TSC2 TP53 NF1 KIAA1549 IDH1 EGFR
10 high grade glioma 31.6 TP53 MIR9-1 MIR21 MIR155 MIR124-1 MGMT
11 brain cancer 31.5 TP53 NF1 MIR9-1 MIR21 MIR155 MIR139
12 allergic disease 31.3 SERPINA3 MIR21 MIR155 H2AC18
13 ganglioglioma 31.3 TSC2 TP53 NF1 H3-3A
14 glioblastoma 31.3 TSC2 TP53 NF1 MIR21 MIR155 MGMT
15 mixed glioma 31.3 TP53 NF1 MGMT IDH2 IDH1 EGFR
16 fibrillary astrocytoma 31.2 TP53 NF1 KIAA1549 IDH2 IDH1 H3-3B
17 toxic encephalopathy 31.2 TP53 SERPINA3 MIR9-1 MIR124-1 H2AC18
18 meningioma, familial 31.2 TP53 SERPINA3 NF1 MGMT KIAA1549 IDH1
19 central nervous system cancer 31.0 TP53 SERPINA3 MIR9-1 MIR21 MIR155 MIR139
20 gemistocytic astrocytoma 31.0 TP53 MGMT IDH2 IDH1 ATRX
21 brain glioma 30.9 TP53 NF1 MGMT KDM4C IDH2 IDH1
22 neurofibroma 30.9 TP53 NF1 EGFR
23 plexiform neurofibroma 30.8 TP53 NF1 EGFR
24 neuroma 30.8 SERPINA3 NF1 MGMT
25 pituitary gland disease 30.7 MIR9-1 MIR139 H2AC18
26 respiratory failure 30.7 SERPINA3 MIR21 MIR155 H2AC18
27 pilomyxoid astrocytoma 30.7 NF1 MGMT KIAA1549 IDH2 IDH1 H3-3B
28 pilocytic astrocytoma of cerebellum 30.6 NF1 KIAA1549 IDH1 H3-3A
29 rhabdoid cancer 30.6 TP53 MIR9-1 KDM4C H2AC18
30 anaplastic oligodendroglioma 30.6 TP53 NF1 MGMT KIAA1549 KDM4C IDH2
31 focal epilepsy 30.6 MIR9-1 MIR21 MIR139 MIR124-1
32 gliomatosis cerebri 30.6 TP53 MGMT KIAA1549 KDM4C IDH2 IDH1
33 mixed oligodendroglioma-astrocytoma 30.6 TP53 MGMT IDH2 IDH1 ATRX
34 skin melanoma 30.6 TP53 MIR21 KDM4C IDH1 H2AC18
35 psychotic disorder 30.6 SERPINA3 MIR9-1 MIR21 KDM4C H2AC18
36 lung benign neoplasm 30.6 TP53 MGMT EGFR
37 obstructive hydrocephalus 30.5 TSC2 NF1 KIAA1549 H3-3B H3-3A
38 lung squamous cell carcinoma 30.5 TP53 MIR9-1 MIR139 H2AC18 EGFR
39 lymphoma, hodgkin, classic 30.5 TP53 MIR9-1 MIR21 MIR155 KDM4C H2AC18
40 atypical teratoid rhabdoid tumor 30.5 TP53 NF1 MIR124-1 KIAA1549 IDH1 H3-3B
41 melanoma, uveal 30.5 TP53 NF1 MIR9-1 KDM4C H2AC18 EGFR
42 anaplastic astrocytoma 30.5 TP53 SERPINA3 NF1 MGMT KIAA1549 KDM4C
43 bap1 tumor predisposition syndrome 30.5 TSC2 TP53 NF1 EGFR
44 dysembryoplastic neuroepithelial tumor 30.5 NF1 KIAA1549 IDH2 IDH1 H3-3B H3-3A
45 cerebrum cancer 30.5 TP53 MGMT KIAA1549 IDH1 H3-3B H3-3A
46 diffuse midline glioma, h3 k27m-mutant 30.5 TP53 MGMT IDH1 H3-3B H3-3A H2AC18
47 leukemia, acute lymphoblastic 30.5 TP53 MIR9-1 MIR21 MIR155 MIR124-1 KDM4C
48 brain stem glioma 30.5 TP53 KDM4C IDH2 IDH1 H3-3B H3-3A
49 leukemia, chronic myeloid 30.4 TP53 NF1 MIR9-1 MIR155 KDM4C H2AC18
50 leukemia, chronic lymphocytic 30.4 TP53 MIR9-1 MIR21 MIR155 KDM4C H2AC18

Graphical network of the top 20 diseases related to Low Grade Glioma:

Diseases related to Low Grade Glioma

Symptoms & Phenotypes for Low Grade Glioma

MGI Mouse Phenotypes related to Low Grade Glioma:

# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.56 EGFR IDH2 KDM4C MGMT MIR139 NF1
2 cellular MP:0005384 9.4 ATRX EGFR H3-3A H3-3B IDH2 KDM4C

Drugs & Therapeutics for Low Grade Glioma

Drugs for Low Grade Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
6 Antimitotic Agents Phase 3
7 Tubulin Modulators Phase 3
8 Pharmaceutical Solutions Phase 3
9 Fluorophosphate Phase 3
10 Alkylating Agents Phase 3
11 Antineoplastic Agents, Alkylating Phase 3
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
Carmustine Approved, Investigational Phase 2 154-93-8 2578
Hydroxyurea Approved Phase 2 127-07-1 3657
Dimethyl sulfoxide Approved, Vet_approved Phase 1, Phase 2 67-68-5 679
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
Nivolumab Approved Phase 2 946414-94-4
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3 135329020
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2 23431961
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
Acetaminophen Approved Phase 2 103-90-2 1983
Trametinib Approved Phase 2 871700-17-3 11707110
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
Olaparib Approved Phase 2 763113-22-0 23725625
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
Vinblastine Approved Phase 2 865-21-4 241903 13342
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
Imatinib Mesylate Phase 2 220127-57-1
35 Antirheumatic Agents Phase 1, Phase 2
36 Anti-Infective Agents Phase 1, Phase 2
37 Antiprotozoal Agents Phase 1, Phase 2
38 Antiparasitic Agents Phase 1, Phase 2
39 Antimalarials Phase 1, Phase 2
40 Antioxidants Phase 1, Phase 2
41 Protective Agents Phase 1, Phase 2
42 Immune Checkpoint Inhibitors Phase 2
43 Antineoplastic Agents, Immunological Phase 2
44 topoisomerase I inhibitors Phase 1, Phase 2
45 Anthelmintics Phase 1, Phase 2
46 Angiogenesis Inhibitors Phase 1, Phase 2
47 Anticonvulsants Phase 1, Phase 2
48 Citrate Phase 1, Phase 2
49 Piperazine citrate Phase 1, Phase 2
50 DMP 777 Phase 1, Phase 2 157341-41-8

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Unknown status NCT02455245 Phase 3 Carboplatin;Vincristine
2 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
5 A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
6 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery Recruiting NCT04316039 Phase 2, Phase 3 Temozolomide
7 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
8 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
9 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
10 LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy Not yet recruiting NCT05566795 Phase 3 DAY101;Chemotherapeutic Agent
11 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Terminated NCT03763422 Phase 3 Temozolomide
12 Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs) Unknown status NCT00575796 Phase 2 Vinblastine Sulphate
13 A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas Completed NCT00782626 Phase 2 everolimus
14 Phase 2 Study of Weekly Vinorelbine in Children With Progressive or Recurrent Low-Grade Gliomas Completed NCT01497860 Phase 2 Vinorelbine
15 Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma Completed NCT02197637 Phase 2 ORAL VINORELBINE
16 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 Everolimus
17 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
18 A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma Completed NCT01635283 Phase 2
19 Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
20 A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma Completed NCT00313729 Phase 2 temozolomide
21 A Phase 2 Study of Vinblastine Sulphate Injection in Children With Recurrent or Refractory Low Grade Glioma Completed NCT00213278 Phase 2 vinblastine sulphate injection
22 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
23 Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
24 SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma Recruiting NCT04923126 Phase 1, Phase 2 Mirdametinib
25 Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults Recruiting NCT04201457 Phase 1, Phase 2 Dabrafenib;Trametinib;Hydroxychloroquine
26 FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors Recruiting NCT04775485 Phase 2 DAY101
27 Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype Recruiting NCT03718767 Phase 2 Nivolumab
28 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
29 A Prospective, Singal-arm Clinical Study of Recombinant Human Endostatin (ENDOSTAR) Combined With Carboplatin and Vincristine in the Treatment of Low-grade Gliomas in Children Recruiting NCT04659421 Phase 2 combined therapy with rh-ES and CV
30 Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm Recruiting NCT04044937 Phase 2 F-18 Fluoroethyltyrosine (FET)
31 A Phase II Study of Vaccinations With HLA-A2 Restricted Glioma Antigen Peptides in Combination With Poly-ICLC for Children With Recurrent Unresectable Low-Grade Gliomas (LGG) Recruiting NCT02358187 Phase 2
32 A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG) Recruiting NCT02840409 Phase 2 Vinblastine;Bevacizumab
33 A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1 Recruiting NCT04544007 Phase 2 Poly ICLC
34 A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Active, not recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
35 A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway. Active, not recruiting NCT03363217 Phase 2 Trametinib
36 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Active, not recruiting NCT03233204 Phase 2 Olaparib
37 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Active, not recruiting NCT03213665 Phase 2 Tazemetostat
38 A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes Active, not recruiting NCT01288235 Phase 2
39 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Active, not recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
40 PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma Terminated NCT02023905 Phase 2 Everolimus;Temozolomide
41 Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas Terminated NCT01338857 Phase 2 Sorafenib (Nexavar)
42 Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma Terminated NCT01887522 Phase 2 Vinblastine + Nilotinib;Vinblastine
43 A Phase 2 Study of the IDH1 Inhibitor, IDH305, for the Treatment of IDH1 Mutated Low Grade Glioma Patients Who Have Measurable 2HG by MR Spectroscopy Withdrawn NCT02987010 Phase 2 IDH305
44 Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery - Randomized Prospective Trial Unknown status NCT02122042 Phase 1
45 Fluorescence Spectroscopy Guided Surgery for Brain Tumors Resection: a Feasibility Study in Human Completed NCT02473380 Phase 1
47 A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas Recruiting NCT03749187 Phase 1 PARP Inhibitor BGB-290;Temozolomide
48 PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas Recruiting NCT04485559 Phase 1 Everolimus;Trametinib
49 A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors Active, not recruiting NCT03429803 Phase 1 DAY101
50 A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas Active, not recruiting NCT01130077 Phase 1

Search NIH Clinical Center for Low Grade Glioma

Genetic Tests for Low Grade Glioma

Anatomical Context for Low Grade Glioma

Organs/tissues related to Low Grade Glioma:

MalaCards : Brain, Temporal Lobe, Cortex, Spinal Cord, Endothelial, Pituitary, Prefrontal Cortex

Publications for Low Grade Glioma

Articles related to Low Grade Glioma:

(show top 50) (show all 2613)
# Title Authors PMID Year
Incidental low grade glioma in young female: An indolent lesion? A case report and a literature review. 62
36410126 2022
The relationship between mental fatigue, cognitive functioning, and employment status in patients with low-grade glioma: a cross-sectional single-center study. 62
34694184 2022
Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. 62
36367046 2022
Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma. 62
36455272 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. 62
36335782 2022
The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis. 62
36345363 2022
Fluorescein-guided resection for pediatric low-grade gliomas: institutional experience on two cases and a narrative literature review. 62
36454311 2022
Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression. 62
36057370 2022
Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology. 62
36329783 2022
robustica: customizable robust independent component analysis. 62
36471244 2022
Assessment of structural disconnections in gliomas: comparison of indirect and direct approaches. 62
35503481 2022
Molecular subtype classification of low-grade gliomas using magnetic resonance imaging-based radiomics and machine learning. 62
35767281 2022
18 F-FDOPA and MRI Findings in a Case of Multiple Sclerosis. 62
35867983 2022
Shuffle-ResNet: Deep learning for predicting LGG IDH1 mutation from multicenter anatomical MRI sequences. 62
36326618 2022
Use of longitudinal functional MRI to demonstrate translocation of language function in patients with brain tumors. 62
36433876 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. 62
35788692 2022
Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer In Silico Analysis. 62
36288884 2022
Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations. 62
36350002 2022
Efficacy of different salvage regimens in progressive unresectable pediatric low-grade glioma. 62
36245827 2022
MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients. 62
36436416 2022
Association of extent of resection and functional outcomes in diffuse low-grade glioma: systematic review & meta-analysis. 62
36404358 2022
Serine hydroxymethyltransferase 1 promotes low-grade glioma progression by activating mTORC1 signaling. 62
36417280 2022
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. 62
36375115 2022
Improved psychotic symptoms following resection of amygdalar low-grade glioma: illustrative case. 62
36443957 2022
Novel TPR::ROS1 Fusion Gene Activates MAPK, PI3K and JAK/STAT Signaling in an Infant-type Pediatric Glioma. 62
36316040 2022
Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis. 62
36319795 2022
Management of epilepsy in brain tumor patients. 62
35838207 2022
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. 62
36201590 2022
Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. 62
35148412 2022
A convolutional neural network model for survival prediction based on prognosis-related cascaded Wx feature selection. 62
35810236 2022
Implementing the WHO Global Initiative for Childhood Cancer in Morocco: Survival study for the six indexed childhood cancers. 62
35796382 2022
Risk factors for early progression of diffuse low-grade glioma in adults. 62
36180935 2022
Pediatric spinal pilocytic astrocytomas form a distinct epigenetic subclass from pilocytic astrocytomas of other locations and diffuse leptomeningeal glioneuronal tumours. 62
36264505 2022
Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). 62
36215122 2022
The need to consider return to work as a main outcome in patients undergoing surgery for diffuse low-grade glioma: a systematic review. 62
35945356 2022
Sex-Specific Differences in Low-Grade Glioma Presentation and Outcome. 62
35667529 2022
Pan-cancer analysis of GALNTs expression identifies a prognostic of GALNTs feature in low grade glioma. 62
35075694 2022
Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case-control study. 62
36029398 2022
Estimating the Prognosis of Low-Grade Glioma with Gene Attention Using Multi-Omics and Multi-Modal Schemes. 62
36290366 2022
Medical Treatment of Pediatric Low-Grade Glioma. 62
36347636 2022
Weighted correlation network analysis identifies multiple susceptibility loci for low-grade glioma. 62
36305248 2022
Presurgical predictors of early cognitive outcome after brain tumor resection in glioma patients. 62
36209618 2022
Contralesional macrostructural plasticity in patients with frontal low-grade glioma: a voxel-based morphometry study. 62
36208304 2022
A Nationwide Evaluation of Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK: Safety. Efficacy, Visual Morbidity and Outcomes. 62
36239316 2022
Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma. 62
36321611 2022
A Personalized Longitudinal Strategy in Low-Grade Glioma Patients: Predicting Oncological and Neural Interindividual Variability and Its Changes over Years to Think One Step Ahead. 62
36294760 2022
[Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers]. 62
36305410 2022
Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas. 62
35940591 2022
Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells. 62
35926818 2022
Language reorganization in patients with left-hemispheric gliomas is associated with increased cortical volume in language-related areas and in the default mode network. 62
36356409 2022

Variations for Low Grade Glioma

Expression for Low Grade Glioma

Search GEO for disease gene expression data for Low Grade Glioma.

Pathways for Low Grade Glioma

GO Terms for Low Grade Glioma

Biological processes related to Low Grade Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of mitophagy GO:1901525 9.46 TSC2 TP53
2 positive regulation of miRNA maturation GO:1903800 9.26 TP53 EGFR
3 isocitrate metabolic process GO:0006102 9.26 IDH2 IDH1
4 glyoxylate cycle GO:0006097 8.92 IDH2 IDH1

Molecular functions related to Low Grade Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.46 MIR9-1 MIR21 MIR155 MIR139
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH2 IDH1
3 mRNA 3'-UTR binding GO:0003730 9.1 TP53 MIR9-1 MIR21 MIR155 MIR139

Sources for Low Grade Glioma

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....